-
AstraZeneca-Daiichi Sankyo Enhertu gets USFDA Breakthrough Therapy Designation in HER2-positive early breast cancer
22 Dec 2025 12:56 GMT
Cambridge: AstraZeneca and Daiichi Sankyo has announced that Enhertu (trastuzumab … , Global Head, R&D, Daiichi Sankyo, said, “This tenth Breakthrough Therapy … drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and …
-
Asian Stocks Mostly Subdued In Thin Trading
25 Dec 2025 10:37 GMT
… Inc., Nippon Paper, Shionogi and Daiichi Sankyo gained 2 to 3.1% …
-
Shanghai Composite Index, Nikkei 225 Close Higher
25 Dec 2025 10:18 GMT
… to 4%.
Pacific Metals, Ajinomoto, Daiichi Sankyo, Nippon Paper, Panasonic, Fanuc, Toto …
-
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report
24 Dec 2025 17:16 GMT
… reports personal fees from AstraZeneca, Daiichi Sankyo, Regeneron, Boehringer Ingelheim, Eli Lilly …
-
<![CDATA[Sacituzumab Govitecan Yields Fewer AEs Vs Chemotherapy in Advanced TNBC]]>
24 Dec 2025 15:26 GMT
… , Arvinas, AstraZeneca, Bayer, Celcuity, Cytomx, Daiichi Sankyo, Dantari, Dignitana, Genentech/Roche … Squibb, Boehringer Ingelheim, Briacell, BridgeBio, Daiichi Sankyo, Jazz Pharmaceuticals/Zymeworks, Gilead …
-
<![CDATA[Breast Cancer Data Affirm Aromatase Inhibitors as Optimal Endocrine Therapy]]>
24 Dec 2025 00:31 GMT
… Pharmaceuticals, Ipsen, Sandoz, Libbs, and Daiichi Sankyo.
References
Lambertini M, Samy F …
-
Continued Scrutiny of Genus Claims: The Written Description and Enablement Requirements for Broad and Previously Undisclosed Subgenera
23 Dec 2025 18:59 GMT
… Enhertu, an ADC, manufactured by Daiichi Sankyo (Daiichi), containing a tetrapeptide linker … patent applications.
1Seagen Inc. v. Daiichi Sankyo Co., Ltd., 2023-2424 (Fed … . 2, 2025).
2Seagen Inc. v. Daiichi Sankyo Co., Ltd., No. 2:2020cv00337 …
-
<![CDATA[Phase 3 Trial of T-DXd Initiated in HER2+ Endometrial Cancer]]>
23 Dec 2025 16:42 GMT
AstraZeneca and Daiichi Sankyo have initiated DESTINY-Endometrial02 (NCT07022483), … Late-Stage Oncology Clinical Development, Daiichi Sankyo, in a news release. “We …
-
<![CDATA[FDA Grants Breakthrough Status to Enhertu for Some HER2+ Early Breast Cancers ]]>
23 Dec 2025 16:30 GMT
… release from AstraZeneca.
AstraZeneca and Daiichi Sankyo’s Enhertu's breakthrough … , Global Head, R&D, Daiichi Sankyo, said: “This tenth breakthrough therapy …
-
<![CDATA[Toxicity Considerations Drive Treatment Strategies in the New Era of NSCLC Therapy]]>
23 Dec 2025 16:44 GMT
… /4nV8h6Bf
Datroway. Prescribing information. Daiichi Sankyo; 2025. Accessed August 27, 2025 …
About
© 1995-2025